TWST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TWST is not a good buy right now for an impatient investor. Price is sitting just above near-term support (39.9) but momentum has turned down (bearish MACD) heading into earnings on 2/2, while hedge funds and insiders have been aggressive sellers. I’d rate it a HOLD (avoid new buying today) until it reclaims the pivot (42.45) or breaks above resistance (~45) with improving momentum.
Trend/structure: Longer-term trend still leans bullish (SMA_5 > SMA_20 > SMA_200), but the recent tape is weakening. Momentum: MACD histogram -0.184 and negatively expanding = downside momentum building. RSI_6 ~45.8 = neutral/soft (not oversold). Levels: Pivot 42.446 (price below pivot is a near-term negative), Support S1 39.915 (current post-market ~40.68 is close—important line in the sand), Resistance R1 44.976 then R2 46.54. Short-term read: biased to chop-to-down unless buyers defend ~39.9 and push back above ~42.45.
Intellectia Proprietary Trading Signals
on 2026-02-02 pre-market: tends to attract attention/volatility.
increases odds of a support retest (~39.
or lower.
Latest quarter: 2025/Q4. Revenue grew to ~$99.01M (+16.88% YoY), showing solid top-line momentum. Gross margin improved to ~51.35% (+13.78% YoY), a notable positive. However, profitability deteriorated: net income fell to about -$27.14M (more negative, -21.69% YoY) and EPS declined to -$0.45 (-23.73% YoY). Summary: improving growth and margins, but losses are still expanding—market focus remains on path-to-profitability and forward guidance.
Recent trend: clearly improving—multiple firms raised price targets in January (Guggenheim to $50, TD Cowen to $43, Evercore to $42) and Barclays remains Overweight (latest PT $39 after prior cut). Overall stance is predominantly bullish (Buy/Outperform/Overweight). Wall Street pros: differentiated DNA synthesis platform, cost/scale advantages, share gains, improving end markets and sector rotation tailwinds. Wall Street cons: competitive intensity, uncertainty around long-term synthetic biology opportunity size, and profitability path still not fully de-risked.
